CLASSYS has reported significant growth in its first-quarter financial results, driven by increased global demand and strategic synergy following its merger with Eruda.
The South Korean beauty medical device company posted an operating profit of 38.8 billion won for the first quarter of this year, a 46.3% increase compared to the same period in 2024. Sales also jumped 53.06% year-on-year to 77.1 billion won.
CLASSYS attributed the growth to the successful and early completion of integration efforts with Eruda, which accelerated synergy and efficiency across the business. The company currently maintains a robust dealer network in more than 80 countries and serves over 18,000 medical professionals worldwide.
Increased global awareness of aesthetic treatments—spurred by international beauty influencers sharing their experiences—has also boosted demand. As a result, CLASSYS has seen rising export sales in key markets including Brazil, Thailand, and Japan.
The company also pointed to strong performance from its key products. Sales of Everesse (known as Voluneur in Korea), which launched in the U.S. last October, have been growing steadily. Meanwhile, global demand for Shrinks Universe—a treatment with a high satisfaction rate—is also on the rise.
Looking ahead, CLASSYS is preparing to launch a next-generation microneedle product in the second half of the year.
“The first quarter delivered strong results thanks to high customer satisfaction and growing awareness of our treatments,” said a CLASSYS spokesperson. “We will continue to pursue aggressive growth strategies to meet our quarterly goals. Our long-term vision is to become the world’s top beauty medical company through energy-based recurring platform (EBRP) solutions, strengthened R&D, licensing, and brand development.”
Related topics:
